前立腺がん治療薬の市場規模、シェア、成長分析：薬剤クラス別、流通チャネル別、地域別 - 産業予測 2025年～2032年

前立腺がん治療薬市場規模は2023年に135億米ドルと評価され、予測期間（2025-2032年）のCAGRは8.4%で、2024年の146億3,000万米ドルから2032年には279億米ドルに成長する見通しです。

世界の前立腺がん治療薬市場は、高齢化と早期診断に対する意識の高まりによって急速に発展しています。治療法の大幅な進歩により、外科手術、放射線療法、化学療法、ホルモン療法、免疫療法、標的療法など多様な治療法が患者に提供されるようになり、市場の成長が加速しています。精密医療への動向は、より個別化された治療選択肢を可能にし、牽引力を増しています。製薬会社や研究機関などの主要な業界企業は、この分野での技術革新のために協力しています。高コスト、副作用、より優れたバイオマーカーの必要性といった課題治療にもかかわらず、新規ドラッグデリバリーシステムやAIの統合を含む革新的なアプローチが、診断や治療方針の決定に変革をもたらしつつあります。併用療法や、免疫療法、遺伝子治療などの代替療法の台頭は、前立腺がん治療薬の展望をさらに再構築するものと思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

前立腺がん治療薬市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• ホルモン療法
  • 黄体形成ホルモン放出ホルモン（LHRH）拮抗薬
  • ザイティガ
  • ゴナックス
  • 黄体形成ホルモン放出ホルモン（LHRH）作動薬
  • ルプロン
  • ゾラデックス
  • エリガード
  • デカペプチル
  • ヴァンタス
  • その他
  • 抗アンドロゲン
  • ザンディ
  • カソデックス
• 化学療法
  • タキソテール
  • ジェフタナ
• 免疫療法
  • プロベンジ
• 標的療法
  • ゾフィゴ
• その他

前立腺がん治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• ドラッグストアと薬局
• オンライン薬局

前立腺がん治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AbbVie（US）
• Amgen（US）
• AstraZeneca（UK）
• Bayer AG（Germany）
• Johnson & Johnson（US）
• Pfizer Inc.（US）
• Novartis AG（Switzerland）
• Merck & Co.（US）
• Sanofi（France）
• Roche（Switzerland）
• Bristol-Myers Squibb（US）
• Eli Lilly and Company（US）
• GlaxoSmithKline（UK）
• Takeda Pharmaceutical Company Limited（Japan）
• Astellas Pharma Inc.（Japan）
• MSD（Merck & Co., Inc.）（US）
• Bayer Healthcare（Germany）
• Daiichi Sankyo Company, Limited（Japan）

結論と推奨事項

Prostate Cancer Therapeutics Market size was valued at USD 13.5 billion in 2023 and is poised to grow from USD 14.63 billion in 2024 to USD 27.9 billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).

The Global Prostate Cancer Therapeutics Market is rapidly evolving, driven by an aging population and increased awareness of early diagnosis. Significant treatment advancements have led to enhanced market growth, with diverse modalities including surgery, radiation, chemotherapy, hormone therapy, immunotherapy, and targeted therapies available for patients. The trend toward precision medicine is gaining traction, allowing for more personalized treatment options. Key industry players, such as pharmaceutical companies and research organizations, are collaborating to innovate within the sector. Despite challenges like high costs, adverse effects, and the need for better biomarkers, innovative approaches, including novel drug delivery systems and AI integration, are transforming diagnostics and treatment decisions. The rise of combination therapies and alternative methods like immunotherapy and gene therapy are set to further reshape the prostate cancer therapeutics landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Therapeutics Market Segments Analysis

Global Prostate Cancer Therapeutics Market is segmented by Drug Class, Distribution Channel and Region. Based on Drug Class, the market is segmented into Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Prostate Cancer Therapeutics Market

A significant catalyst for the Global Prostate Cancer Therapeutics Market is the rising aging population. With advancing age, individuals face a heightened risk of developing prostate cancer, thereby expanding the pool of patients in need of effective treatment options. This demographic shift, especially prevalent in developed areas, plays a crucial role in driving the growth and demand for therapies aimed at combatting prostate cancer. As the number of older adults increases, so too does the necessity for innovative therapeutic solutions, further propelling the market forward in response to this essential healthcare need.

Restraints in the Prostate Cancer Therapeutics Market

A significant limitation in the Prostate Cancer Therapeutics market is the prohibitive cost of treatments. The financial burden stemming from various modalities, including diagnosis, surgery, radiation, chemotherapy, hormone therapies, and targeted treatments, can be substantial. This high expense presents considerable challenges for both patients and healthcare systems, potentially restricting access to essential care, especially in areas with constrained healthcare resources or among patients lacking sufficient insurance coverage. Consequently, these financial hurdles may impede market expansion and adversely affect patient outcomes, highlighting the need for more affordable therapeutic options in this sector.

Market Trends of the Prostate Cancer Therapeutics Market

In the Prostate Cancer Therapeutics market, a significant trend is the rising emphasis on precision medicine. This approach seeks to customize treatment strategies based on individual patient characteristics, including genetic profiles, biomarkers, and specific disease factors. As research advances in molecular profiling technologies and the understanding of genetic mutations linked to prostate cancer, there is a growing shift towards personalized, targeted therapies. This trend not only aims to improve treatment efficacy but also to mitigate side effects, leading to enhanced patient outcomes. Consequently, pharmaceutical companies are increasingly investing in tailored therapies, reflecting a paradigm shift in prostate cancer management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Prostate Cancer Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Hormonal Therapy
  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
  • Zytiga
  • Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
  • Lupron
  • Zoladex
  • Eligard
  • Decapeptyl
  • Vantas
  • Others
  • Anti-Androgen
  • Xtandi
  • Casodex
• Chemotherapy
  • Taxotere
  • Jevtana
• Immunotherapy
  • Provenge
• Targeted Therapy
  • Xofigo
• Others

Global Prostate Cancer Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Prostate Cancer Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD (Merck & Co., Inc.) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Healthcare (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations